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Abstract
Interstitial lung disease (ILD) in infants and children comprises a large spectrum of rare respiratory disorders that
are mostly chronic and associated with high morbidity and mortality. These disorders are characterized by inflam-
matory and fibrotic changes that affect alveolar walls. Typical features of ILD include dyspnea, diffuse infiltrates on
chest radiographs, and abnormal pulmonary function tests with restrictive ventilatory defect and/or impaired gas
exchange. Many pathological situations can impair gas exchange and, therefore, may contribute to progressive
lung damage and ILD. Consequently, diagnosis approach needs to be structured with a clinical evaluation requir-
ing a careful history paying attention to exposures and systemic diseases. Several classifications for ILD have been
proposed but none is entirely satisfactory especially in children. The present article reviews current concepts of
pathophysiological mechanisms, etiology and diagnostic approaches, as well as therapeutic strategies. The follow-
ing diagnostic grouping is used to discuss the various causes of pediatric ILD: 1) exposure-related ILD; 2) systemic
disease-associated ILD; 3) alveolar structure disorder-associated ILD; and 4) ILD specific to infancy. Therapeutic
options include mainly anti-inflammatory, immunosuppressive, and/or anti-fibrotic drugs. The outcome is highly
variable with a mortality rate around 15%. An overall favorable response to corticosteroid therapy is observed in
around 50% of cases, often associated with sequelae such as limited exercise tolerance or the need for long-term
oxygen therapy.
Definition
Interstitial lung disease (ILD) in infants and children
represents a heterogeneous group of respiratory disor-
ders that are mostly chronic and associated with high
morbidity and mortality (around 15%) [1,2]. These dis-
orders are characterized by inflammatory and fibrotic
changes that affect alveolar walls. Typical features of
ILD include the presence of diffuse infiltrates on chest
radiograph, and abnormal pulmonary function tests with
evidence of a restrictive ventilatory defect (in older
children) and/or impaired gas exchange [3].
Classification
There have been many different approaches to the clas-
sification of ILD, with major shifts based on clinical
investigation, improvement in chest imaging, and colla-
boration with pathologists. In 1998, Katzenstein and
Myers proposed four histopathologically distinct sub-
groups of idiopathic interstitial pneumonias: usual
interstitial pneumonia (UIP), desquamative interstitial
pneumonia (DIP) and a closely related pattern termed
respiratory bronchiolitis-associated ILD, acute interstitial
pneumonia (formerly Hamman-Rich syndrome), and
non specific interstitial pneumonia (NSIP) [4]. In 2002,
an international multidisciplinary consensus classifica-
tion of idiopathic interstitial pneumonias was proposed
by the American Thoracic Society (ATS)/European
Respiratory Society (ERS) [5]. This classification defined
a set of histologic pattern that provided the basis for
clinico-radiologic-pathologic diagnosis, with the final
pathologic diagnosis being made after careful correlation
with clinical and radiologic features. However, as dis-
cussed in several reports, the classification schemes of
adult ILD are not satisfactory for the pediatric cases
which seem to comprise a broader spectrum of disor-
ders with a more variable clinical course [6]. In addition,
pediatric histologic patterns often do not resemble
pathologic features of lung tissues from adults and some
forms are only observed in children younger than
2 years.
Among the proposed classifications for pediatric ILD,
one strategy frequently used is to separate the primary
pulmonary disorders and the systemic disorders with
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has been introduced which is based on the concept that
some pediatric ILD are observed more frequently in
infants, while others are more specific to older children.
The last ERS monography on ILD provided a chapter
on pediatric classification which is based on a clear
distinction between children aged 0-2 years and children
over 2 years-old [7]. Indeed the stage of lung develop-
ment and maturation should be taken into consideration
when approaching a diagnosis of pediatric ILD. In this
view, a new term “diffuse lung disease” has recently
been introduced that comprises a diverse spectrum of
lung disorders with impaired gas exchange and diffuse
infiltrates by imaging. These disorders, more prevalent
in young children, include diffuse developmental disor-
ders, lung growth abnormalities, neuroendocrine cell
hyperplasia and pulmonary interstitial glycogenosis, sur-
factant dysfunction disorders, disorders related to sys-
temic diseases, disorders of immunocompromised host,
and disorders of normal host caused by various insults
such as aspiration syndrome or infections [8]. Some dis-
eases are mostly observed in older children such as sys-
temic diseases, idiopathic disorders as described in
adults (DIP, UIP, NSIP and lymphoid interstitial pneu-
monia (LIP)), unclassifiable ILD and also infectious dis-
orders [9].
It is important to point out that the pathologic pro-
cesses underlying the so-called diffuse lung diseases
involve not only the alveolar structure but also the distal
part of the small airways and the conducting zone, i.e.
the terminal bronchioles. Terminal bronchioles are lined
with a simple cuboidal epithelium containing Clara cells,
basal cells and a limited number of ciliated cells. Clara
cells secrete nonsticky proteinaceous compounds to
maintain the airway in the smallest bronchioles, which
constitute the quiet zone between the conducting and
the respiratory lung zones [10]. The terminal bronch-
ioles are surrounded by a spiral of smooth muscle. Each
of the terminal bronchioles divides to form respiratory
bronchioles which contain a small number of alveoli.
Consequently, the term of diffuse lung disease refers to
disorders that can affect both the distal part of the con-
ducting and the respiratory lung zones, and include ILD
as well as pathological processes leading to obstruction/
obliteration of small airways [8]. Therefore, diffuse lung
diseases encompass a broader group of diseases than
ILD which refers to disorders that affect the respiratory
function of the lung and consequently the pulmonary
structure responsible of the diffusion of gases between
blood and air (i.e. the alveolar epithelium, the intersti-
tium, and the pulmonary capillary endothelium).
The present review focuses on ILD in immunocompe-
tent children, and excludes pulmonary consequences of
previous lung injury in situations of chronic aspiration
syndromes, resolving acute respiratory distress syn-
drome, and bronchopulmonary dysplasia.
Epidemiology
An estimated prevalence of 3.6 per million has been
reported by Dinwiddie and coworkers through a
national survey of chronic ILD in immunocompetent
children in the United Kingdom and Ireland over a
three year period (1995-1998) [1]. This prevalence is
certainly under-estimated due to the lack of standar-
dized definitions and the absence of organized reporting
systems. From the limited published data composed
mainly of case reports and small series, it seems that
pediatric ILD occurs more frequently in the younger age
and in boys [11]. In addition, nearly 10% of cases appear
to be familial [12].
Pathophysiology
Critical role of the alveolar epithelium
The understanding of the mechanisms underlying the
development and progression of ILD remains elusive
[13,14]. Indeed, for a long time, chronic ILD and pul-
monary fibrosis were believed to result mainly from
chronic inflammation following an initial injury to the
alveolar epithelial lining [15,16]. In cases of limited
injury, it was thought that the reparative attempt could
reverse the trend toward fibrosis. By contrast, in situa-
tions of continuing injury, the repair process driven by
inflammatory molecules produced by the local cells will
result in scarring and structural changes. Therefore, by
targeting the inflammatory response, the belief was that
fibrosis could be prevented or controlled. This theory
explains the large use of anti-inflammatory therapy with,
however, limited clinical efficacy.
Based on clinical and experimental observations, a
new paradigm has progressively emerged with the alveo-
lar epithelium being viewed as a key actor in the devel-
opment of ILD [17-19]. Following injury, alveolar
epithelial cells (AEC) may actively participate in the
restoration of a normal alveolar architecture through a
coordinated process of re-epithelialization, or in the
development of fibrosis through a process known as
epithelial-mesenchymal transition (EMT) [20]. Complex
networks orchestrate EMT leading to changes in cell
architecture and behaviour, loss of epithelial characteris-
tics and gain of mesenchymal properties. The reasons
for epithelial cell loss and inappropriate re-epithelialisa-
tion are still debated, but ongoing apoptosis is believed
to be a key component in the progression of the disor-
der [21]. Prolonged denudation of the basement mem-
brane contributes to altered interactions and cross-talk
between AECs and mesenchymal cells, resulting in pro-
found modifications of cell functions with imbalanced
production of oxidants, proteases, and polypeptide
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as Transforming Growth Factor (TGF)-b and Endothelin
(ET)-1. A consequence is the perpetuation of a vicious
cycle with TGF-b promoting epithelial cell apoptosis,
which in turn increases the local production of TGF-b
[ 2 2 ] .E T - 1i sa l s oc o n s i d e r e dt ob ea ni m p o r t a n ta c t o r ,
based on the current knowledge of its numerous func-
tions including fibroblast and smooth muscle cell mito-
gen, and stimulant of collagen synthesis [23,24]. Recent
studies showed that ET-1 is produced by AEC, and
could induce alveolar EMT via stimulation of endogen-
ous TGF-b production.
Multiple causes and pathways
ILD may be caused by myriad etiologies with differing
prognoses and natural history. Indeed, multiple factors
may injure the alveolar epithelium and initiate the devel-
opment of ILD [25]. The initiating injury can be intro-
duced through the airways and the circulation, or can
occur as a result of sensitization. Consequently, the
mechanisms underlying disease progression will be
influenced by the causative event as well as by the host
and the environment. These mechanisms are developed
through interactions of multiple pathways, which
include apoptotic pathways, developmental pathways,
and endoplasmic reticulum (ER) associated pathways
(Figure 1).
Apotosis plays a central role in lung remodeling asso-
ciated with ILD [26]. An important molecule in the
events associated with epithelial cell apoptosis is TGF-b,
which is overexpressed in ILD. Downstream events
linked to upregulation of TGF-b include modifications
in the expression of various components of the cell
cycle machinery, mainly the cyclin-dependent kinases
(CDK) system that plays an essential role in ensuring
proper cell cycle progression. Recently, much work has
been focused on the protein p21cip1, a member of the
CDK inhibitor family. This protein promotes cell cycle
arrest to apoptosis in cases of cellular DNA damage.
Interestingly, upregulation of p21cip1 has been reported
in the lung tissues of patients with pulmonary fibrosis,
primarily in hyperplastic alveolar epithelial cells [27]
The increased expression of p21cip1 can favour the pro-
cess of epithelial cell apoptosis. Apoptotic cells can also
produce TGF-b. A consequence would be the perpetua-
tion of a vicious cycle with TGF-b promoting epithelial
cell apoptosis, which in turn increases the local produc-
tion of TGF-b.
Recently, it has been suggested that genes associated
with lung development and embryonic pathways could
be involved in aberrant epithelium-mesenchymal cross-
talk and epithelial plasticity, and could therefore partici-
pate in the development of chronic ILD. Selman and
coworkers reported that lung fibrosis is characterized by
Figure 1 Mechanisms and pathways involved in the response of the alveolar structure of the lung to injury. Abbreviation: Transforming
Growth Factor (TGF)-b.
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extracellular matrix, smooth muscle differentiations, and
genes associated with lung development [28-31]. During
EMT in the embryonic period, cells undergo a switch
from a polarized epithelial phenotype to a highly motile
mesenchymal phenotype [32]. Molecular processes gov-
erning EMT are induced by a cooperation of receptor
tyrosine kinases or oncogenic Ras (RTK/Ras) pathway
and TGF-b signaling [33]. Recently, additional pathways
and effectors have been reported to play a role in the
induction of EMT, such as Wnt//b-catenin, Notch and
Sonic hedgehog signalling [34].
Recent reports strongly suggest that the ER stress may
represent an important mechanism of the altered repair
process observed in the alveolar epithelium of fibrotic
lung [35]. Situations associated with abnormal regulation
of the cascade of events leading to the formation of
mature protein result in either misfolding or mistarget-
ing of the protein. These events trigger induction of
intracellular aggregate formation and ER stress, which
can lead to cell death through apoptosis and autophagic
pathways [36,37]. Several stimuli including oxidant-anti-
oxidant imbalance, viral proteins, inflammatory mole-
cules, nutrient deprivation may induce ER stress [38,39]
(Figure 2). Among the cytoprotective mechanisms avail-
able are the ER chaperones such as binding immunoglo-
bulin protein (BiP). Interestingly, mutant BiP mice have
been reported to die within several hours of birth from
respiratory failure due to impaired secretion of pulmon-
ary surfactant by type 2 AEC. In these animals, expres-
sion of surfactant protein (SP)-C was reduced and the
lamellar bodies were malformed, indicating that BiP
Figure 2 Alveolar structure disorder-associated ILD and ER stress. The (Endoplasmic Reticulum) ER and its protein maturation machinery
allow the synthesis of mature secretory and membrane proteins with specific folded conformation. In situations of stress induced by genetic
mutations or environmental factors, unfolded or misfolded proteins are retained in the ER and induce a defence mechanism called the ER stress
response. The induction of ER chaperones is critical to increase the ER folding capacity allowing the production of correctly folded protein.
When this defence mechanism is impaired, the misfolded proteins can either be degraded by the proteasome or form protein aggregates.
Protein aggregates are toxic and can cause conformational diseases. Within the alveolar epithelium, misfolding of SP-C could trigger induction of
intra-cellular aggregate formation and ER stress, with consequently development of alveolar structure disorder-associated ILD and conformational
disease.
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Several recent reports suggest the possible implication
of ER stress in ILD, with activation of stress response
markers in fibrotic lung tissues.
Surfactant deficiency and stem cell dysfunction
It is now well established that surfactant dysfunction
plays an important role in the development and progres-
sion of ILD. Pulmonary surfactant is a multimolecular
complex constituted of phospholipids and proteins
secreted by type 2 AEC into the alveolar space. It
assures alveolar stability by reducing surface tension
along the epithelial lining and this role involves mainly
the lipids and the specific hydrophobic SP, SP-B and
SP-C. Other important players in surfactant metabolism
include the ATP-binding cassette, sub-family A, member
3 (ABCA3) and the thyroid transcription factor 1
(TTF-1).
Surfactant deficiency can be induced by a number of
primitive and secondary mechanisms. Among them are
genetic defects with mutations in SP-B gene (SFTPB)a s
well as genes coding for SP-C (SFTPC), ABCA3, and
TTF-1 [41-43]. More than 30 SFTPB (located on chro-
mosome 2) mutations have been identified among
patients with a congenital deficiency in SP-B. For
SFTPC located on chromosome 8, at least 35 mutations
have been described, localized primarily in the COOH-
terminal Brichos domain [44,45]. A proposed function
of the Brichos domain is a chaperone-like activity,
which could prevent misfolding and aggregation of the
parent protein. Alterations in the Brichos domain could
therefore lead to diseases through mechanisms related
to abnormal protein processing and cell toxicity [46].
Recently, several studies have also documented the role
of ABCA3 deficiency in ILD. ABCA3 functions in the
transport of surfactant lipids into lamellar bodies and is
required to maintain pulmonary surfactant phospho-
lipid homeostasis. Another contributor of ILD is TTF-1
(NK2 homeobox 1) dysfunction. TTF-1 is a critical reg-
ulator of transcription for the surfactant protein SP-B
and SP-C. It is encoded by a gene located on chromo-
some 14q13 and is composed of three exon and two
introns [47]. It is expressed in the thyroid, brain and
lung.
Stem cell dysfunction represents a new domain of
investigation. Alveolar epithelium regeneration and
repair requires activation and proliferation of tissue-resi-
dent (progenitor) cells and their differentiation to
replace the damaged cells [48]. However, unlike cancer
cells, stem cells are not immortal and display decreasing
telomere length with aging [49]. Telomere shortening
has been documented to be associated with reduced
capacity for stem cell renewal, and decreased activity of
telomerase, the polymerase responsible for telomere
maintenance. The stem cells of the alveolar epithelium
are the type 2 AEC, and expression of telomerase has
been documented in these cells [48]. Experimental stu-
dies have also indicated that telomerase is expressed
mainly during lung development with a peak expression
before birth followed by a decrease to nearly undetect-
able levels in mature alveolar epithelium. Interestingly,
telomerase expression and activity could be reinduced in
normal quiescent type 2 AEC exposed to oxidative stress
[50]. The current understanding is that a population of
type 2 AEC may have the capacity to survive injury
through telomerase activation, and consequently may be
responsible for repopulation of the damaged alveolar
epithelium. On the basis of reports of pulmonary disor-
ders in dyskeratosis congenita (a rare hereditary disease
of poor telomere maintenance), recent and exciting find-
ings have documented mutations in the telomerase gene
in familial idiopathic pulmonary fibrosis [51]. In addi-
tion, it is likely that environmental factors such as
inflammation, oxidative stress, or virus infection may
modify telomerase activity and account for the develop-
ment of organ-specific disease associated with telomer-
ase dysfunction. In this view, new data in chronic
respiratory diseases support the concept that alveolar
stem cell dysfunction may play an important role in the
rate of progression or severity in ILD [52]. The question
whether telomerase mutations or telomere dysfunction
may be implicated in pediatric ILD needs to be
addressed in prospective studies, one possible tool being
determination of telomere length in circulating
leukocytes.
Role of age
The frequency of lung fibrotic disorders is much lower
in children than in adults. Some clinical situations have
features certainly unique to children, but many of these
diseases overlap their adult counterparts with the pri-
mary event being injury and damage of the alveolar
epithelium [11,13]. Yet, the overall outcome and prog-
nosis of the diseases in children are thought to be less
severe than in adult patients. In addition, pediatric ILD
is more responsive to therapeutic strategies than adult
ILD [9]. These differences may be explained by the
types of initial injury, which may not be similar due to
changes in the host environment. Another explanation
is the modifications of the process of wound healing
with age. Comparison of the response to injury in foetal
and adult skin shows clear differences [53]. Skin wound
healing in the foetus is characterized by complete regen-
eration of the skin and the absence of scar formation.
Progressively with age, the skin looses the capacity to
regenerate the original tissue architecture with the result
being scar formation that extends outside the wound
bed. The process of healing involves the coordinated
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remodeling, predominantly by polypeptide growth fac-
tors [54]. The slowing of wound healing that occurs in
the aged may be related to changes in the activity of
these various regulatory factors. In a study on the role
of aging in the development of cardiac fibrosis in the
rabbit, differences in the cascade of events leading to
myocardial remodeling were observed, with mainly the
presence of more myofibroblasts synthesising collagen
and expressing high levels of TGF-b in older animals
[55]. A study of growth factors involved in skin wound
healing in young and aged mice also showed age-depen-
dent changes. Expression of all the fibroblast growth
factors was diminished in aged mice, even in healthy
skin. In addition, the post-wound regulation of expres-
sion of these factors and of TGF-b was less pronounced
a n ds l o w e rt h a ni ny o u n gm i c e .T h e s ef i n d i n g sa r ei n
agreement with data observed in muscle that indicated
significant alterations in the TGF-b production with age
[56,57]. Other potential mechanism is linked to the
observation that injury in adult tissues does in certain
circumstances stimulate tissue regeneration, depending
on the presence of small subsets of primitive stem cells.
Stem cells are the self-renewing, primitive, undifferen-
tiated, multipotent source of multiple cell lineages [49].
While such cells are critical for development and growth
through childhood, residual pools of adult stem cells are
hypothesized to be the source of the frequently limited
tissue regeneration and repair that occurs in adults [58].
Unlike embryonic stem cells, adult stem cells are not
immortal, and show decreasing telomere length with
increasing age. The naturally limited replacement capa-
city of such endogenous stem cell pools may occur via
exhaustion of the stem cell pool or arise as a conse-
quence of inherited or acquired mutations that alter
proper stem cell function [59]. The limited life span of
cells may result from replicative senescence in response
to various stresses including DNA damage, oxidants,
and telomere erosion [52]. All these forms of injury
have been documented in the lung from adult patients
with ILD.
Diagnosis of ILD
Clinical presentation
The prevalence of children ILD is higher in the younger
patients: more than 30% of patients are less than 2 years
at diagnosis, as recorded by the recent ERS Task Force.
7% have parental consanguinity and nearly 10% of case
siblings were affected by similar diseases. There is a
male predominance with a sex ratio of 1.4. The present-
ing clinical manifestations are often subtle and non-
specific. The onset of symptoms is, in most cases, insi-
dious and many children may have had symptoms for
years before the diagnosis of ILD is confirmed. However,
the majority of patients has symptoms for less than one
year at the time of initial evaluation. The clinical mani-
festations vary from asymptomatic presentation with
radiological features suggestive of ILD to more charac-
teristic presence of respiratory symptoms and signs such
as cough, tachypnea and exercise intolerance [9,60].
These varying presentations are also reflected in the
report published by Fan et al. who systematically evalu-
ated the clinical symptoms and physical findings of 99
consecutive children with ILD [2]. Common symptoms
at presentation included cough, dyspnea, tachypnea and
chest wall retraction, exercise limitation and frequent
respiratory infections. Cough is observed in almost 75%
of the patients, is normally non-productive and does not
disturb sleep. Tachypnea is observed in 80% of patients
and is usually the earliest and most common respiratory
symptom. Unexplained fever is also reported in almost
one third of infants. Failure to thrive (37%), tiring dur-
ing feeding and weight loss are also common symptoms,
mainly in young patients. Although a history of wheez-
ing may be elicited in almost 50% of the patients,
wheezing is documented by physical examination in
only 20% of the cases.
The frequent clinical findings are inspiratory crackles
(44%), tachypnea and retraction. In a child with a nor-
mal birth history, these are strongly suggestive of ILD.
Other findings associated with an advanced stage of
lung disease include finger clubbing (13%) and cyanosis
during exercise or at rest (28%) [9,61]. During physical
examination it is essential to check the presence of asso-
ciated non-respiratory symptoms such as joint disease,
cutaneous rashes, and recurrent fever suggestive of col-
lagen-vascular disorders. Details should also be obtained
on precipiting factors such as feeding history, infections,
or exposure to dust and drugs. In addition, information
on relatives or siblings with similar lung conditions
should be gathered.
Chest imaging
Plain radiographs are usually performed in a child sus-
pected of ILD at first presentation, but the information
provided is often limited and the key chest imaging tool
for diagnosis is the High Resolution Computed Tomo-
graphy (HRCT), which can visualize the parenchymal
structure to the level of the secondary pulmonary lobule.
HRCT technique for ILD diagnosis has been exten-
sively discussed [62-64]. To optimise spatial resolution,
there is a general agreement to use thin sections, the
smallest field of view and a sharp resolution algorithm.
The most common HRCT feature of ILD is widespread
ground-glass attenuation. Intralobular lines, irregular
interlobular septal thickening and honeycombing are
less common findings. Large subpleural air cysts in the
upper lobes adjacent to areas of ground-glass opacities
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These cysts are interpreted as paraseptal or irregular
emphysema. HRCT is useful for ILD diagnosis and
selection of lung area to be biopsied. It is proposed that
it also may contribute to monitor disease activity and/or
severity. However, evaluation is still needed to support a
role of HRCT as a follow up tool in pediatric patients.
Pulmonary function testing
Pulmonary function testing (PFT) techniques are well
established in children and adolescents. However, chil-
dren aged 2-6 years represent a real challenge in pul-
monary function assessment as they cannot be sedated
and find it difficult to cooperate with all respiratory
manoeuvres. In 2007, an ATS and ERS statement on
PFT in preschool children summarized the current
knowledge on the PFT techniques suitable for young
children [65,66].
Although PFT does not provide specific information,
it represents a useful investigation for both the diagnosis
and the management of ILD [11]. Generally, in ILD,
pulmonary function abnormalities reflect a restrictive
ventilatory defect with reduced lung compliance and
decreased lung volumes [67-69]. Vital capacity (VC) is
variably diminished; the decrease in total lung capacity
(TLC) in general is relatively less than in VC. Functional
residual capacity (FRC) is also reduced but relatively less
than VC and TLC, and residual volume (RV) is generally
preserved; thus the ratios of FRC/TLC and RV/TLC are
often increased. Airway involvement is observed only in
a minority of patients. Lung diffusing capacity of carbon
monoxide (DLCO) or transfer factor (TLCO) is often
markedly reduced and may be abnormal before any
radiological findings. However, DLCO corrected for
lung volume may also be normal in many children.
Hypoxemia as defined by a reduced resting arterial oxy-
gen saturation (SaO2) or a reduced resting arterial oxy-
gen tension is often present. Hypercarbia occurs only
late in the disease course. During exercise the above
described dysfunctions become even more pronounced.
Thus, gas exchange during exercise might be a more
consistent and sensitive indicator of early disease [3].
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) usefully provides speci-
mens for cytological examination, microbial cultures,
and molecular analysis. Besides infections, BAL can be
of diagnostic value in several situations. In the context
of pulmonary alveolar proteinosis, BAL abnormalities
are characterized by milky appearance fluid, abundant
proteinaceous periodic acid schiff positive material, and
presence of foamy alveolar macrophages (AM) [70].
BAL can also be diagnostic for pulmonary alveolar hae-
morrhage [11]. This diagnostic is easy when the BAL
f l u i dh a sab l o o d yo rp i n kc o l or, but its gross appear-
ance may be normal. Microscopic analysis may then be
of value by documenting the presence of red blood cells
in AM or haemosiderin laden AM [71]. Among other
situations, the diagnosis of Langerhans cell histiocytosis
can be performed with the use of the monoclonal anti-
b o d i e sr e v e a l i n gt h ep r e s e n c eo fC D 1 ap o s i t i v ec e l l s( i n
more than 5% of the BAL cells) [72]. Lipid disorders
with lung involvement represent another indication of
BAL. This includes congenital lipid-storage diseases
(Gaucher’s disease and Niemann-Pick disease) or
chronic lipid pneumonia due to chronic aspiration
[73,74]. However, in cases of aspiration syndromes,
the presence of lipid laden AM is sensitive but not
specific [75].
In other pathological situations, BAL can usefully
serve to direct further investigations. Accumulation of
BAL T-lymphocytes with prevalence of CD4+ cells is
suggestive of sarcoidosis, whilst prevalence of CD8+
cells is suggestive of hypersensitivity pneumonitis [76].
Also, an increase in BAL eosinophils suggests pulmon-
ary infiltrates associated with eosinophilia syndromes
[77]. Depending of the underlying diseases, a number of
cellular and molecular investigations can be proposed
including the studies of various surfactant components,
phospholipids and apoproteins [78].
Tissue biopsies
With increasing recognition of the different patterns of
ILD and their clinical significance, histological investiga-
tion has become increasingly important. Depending on
disorder presentation, biopsy may concern more accessi-
ble organs than the lung such as the skin or the liver in
sarcoidosis. Histological evaluation of lung tissue usually
represents the final step in a series of diagnostic
approaches.
Different methods may be used to obtain lung tissue.
The major difference between individual methods lies
mainly in balancing invasiveness against the potential
for obtaining adequate and sufficient tissue for diagno-
sis. The techniques of choice are open lung biopsy and
video assisted thoracoscopy biopsy. In children, open
lung biopsy usually provides sufficient tissue with few
complications related directly to the biopsy procedure
[79]. Video assisted thoracoscopy biopsy is an alternative
to open lung biopsy, and it has been shown that the
procedure can be safely performed, even in small chil-
dren [80]. The place of other methods like transbron-
chial lung biopsy and percutaneous needle lung biopsy
in appropriate diagnosis of pediatric patients with ILD
has to be established [81-83].
The lung histological patterns that can be observed
in ILD have been reviewed by the ATS/ERS [5]. In
children, they include mainly: DIP, NSIP, and LIP. DIP
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alveolar septa, scattered mixed inflammatory cells and
minimal fibrosis. Many alveolar spaces are lined by
hyperplastic type 2 AEC. Recently, association with
surfactant disorders has been reported [41,84-86].
NSIP encompasses a broad spectrum of abnormalities
with varying degrees of alveolar wall inflammation or
fibrosis. The cellular pattern of NSIP is characterized
by mild to moderate interstitial chronic inflammation
and type 2 AEC hyperplasia in inflammation areas. It
h a sb e e nr e p o r t e di nav a r i e t yo fu n d e r l y i n gc o n d i t i o n s
including connective tissues diseases and surfactant
disorders. LIP features include a marked diffuse infil-
trate of mature lymphocytes, plasma cells and histio-
cytes within the pulmonary interstitium, particularly
the alveolar walls. They are often associated with either
connective tissues disorders or immunodeficiency
states, both congenital and acquired [9]. Another pat-
tern described mainly in adults is diffuse alveolar
damage (DAD), which includes diffuse homogeneous
thickening of alveolar interstitial walls with myofibro-
blast accumulation, prominent type 2 AEC hyperplasia
and atypia, and hyaline membranes containing surfac-
tant proteins and cellular debris [87]. Usual interstitial
pneumonia (UIP) is rare in children [88]. It is charac-
terized by severe remodeling of the alveolar structure
with heterogeneous appearance consisting of contigu-
ous areas of normal lung, dense scarring, and bronch-
iolar abnormal proliferation. Interstitial inflammation
is usually mild to moderate. Histologic patterns of ILD
unique to infancy are described below.
Other tests
Laboratory tests are used to exclude a number of
respiratory diseases in childhood that does not typically
present with ILD such as chronic aspiration syndromes,
resolving acute respiratory distress syndrome, tuberculo-
sis, cystic fibrosis, bronchopulmonary dysplasia and dif-
fuse pulmonary disease such as cystic fibrosis.
Laboratory tests also verify the absence of immunodefi-
ciencies [3].
When these conditions have been eliminated, the
spectrum of investigations that should be performed for
t h ed i a g n o s t i ca p p r o a c hw i l lb eg u i d e db yt h eh i s t o r y
and clinical presentation in each individual child. These
investigations are discussed below for the various disor-
ders. In addition, an increasing number of blood and
BAL biomarkers for evaluation of disease severity and
progression is currently investigated. The studied mole-
cules include various cytokines and chemokines, surfac-
tant protein D, Krebs von den Lungen-6 antigen (KL-6),
matrix metalloproteinases MMP1 and MMP7 and
defensins [89-92].
Etiological diagnosis of ILD
A large number of pathological situations can impair gas
exchange and contribute to progressive lung damage
and ILD. Consequently, diagnosis approaches need to be
organized by cause, with a clinical evaluation requiring a
careful history paying attention to exposures and sys-
temic diseases. Indeed, in a number of pathological
situations, no final diagnos i si sp r o p o s e da n dt h ec o n -
c l u s i o nr e p o r t e db yt h ep h y s i c i a ni nc h a r g eo ft h e
patient is ILD of unknown cause. However, information
from recent studies highlights the concept that lung
insults caused by substances from the environment or in
the context of systemic diseases are largely under-esti-
mated and should be more often discussed considered
in the diagnostic process. Based on this consideration,
the following diagnostic grouping for pediatric ILD can
be considered 1) exposure-related ILD; 2) systemic dis-
ease-associated ILD; 3) alveolar structure disorder-asso-
ciated ILD; and 4) ILD specific to infancy.
Accordingly, a step-by-step etiological diagnostic
approach is required and is summarized in Figure 3.
Once the diagnosis of ILD is established on clinical,
radiological, and functional findings, a careful history
should be obtained for potential exposure-related dis-
eases leading to discuss the need for specific serum anti-
bodies against offending antigens. The following step
focuses on the search for systemic disease associated
ILD, oriented by the presence of clinical and functional
extra-pulmonary manifestations. In such situations,
additional investigations should include specific serum
antibodies and possibly tissue biopsies in organs other
than the lung. Finally, elimination of these 2 groups of
causes with a lung restricted expression of the disease
allows discussing the potential interest of a lung biopsy.
Exposure-related ILD
Exposure-related disease refers to diseases caused by a
sufficient level of exposure (dose) to components with
target organ contact, and subsequent biologic changes
and clinical expression. Many agents have been asso-
ciated with pulmonary complications of various types
including ILD. The adult literature has provided exten-
sive lists of candidate molecules [93]. In children, the
potential involvement of these molecules is not similar
as the environmental conditions and the use of thera-
peutic drugs differ. It is important to point out that
exposure-related diseases are certainly under-estimated
in the pediatric age. One reason is linked to the fact
that the diagnosis is less often discussed than in adults
as pediatricians and other child health care providers do
not usually have the expertise necessary to take an
environmental history. In this review, the most frequent
causes of exposure-related ILD are discussed.
Clement et al. Orphanet Journal of Rare Diseases 2010, 5:22
http://www.ojrd.com/content/5/1/22
Page 8 of 24Hypersensitivity pneumonitis
Hypersensitivity pneumonitis (HP) is a cell-mediated
immune reaction to inhaled antigens in susceptible per-
sons [94,95]. In children, HP is often associated with
exposure to antigens in the home environment as well
as with certain hobbies. The most frequent types of HP
include bird fancier’s diseases, humidifier lung diseases,
and chemical lung diseases. Bird fancier’s diseases are
induced by exposure to birds with the antigens being
glycoproteins in avian droppings, and on feathers.
Importantly, respiratory symptoms in exposed patients
who have only one pet bird at home should raise the
suspicion of HP [96]. Humidifier lung diseases (air con-
ditioner lung, misting fountain lung, basement lung dis-
eases) are caused mainly by free-living amoeba and
nematodes, as well as bacteria and fungi. Chemical lung
diseases can be induced by various inorganic antigens
such as those from vaporized paints and plastics. Low-
molecular-weight chemicals may react with proteins in
the airways, thus forming complete antigens. Once
exposure history is obtained, additional information is
required and includes biologic tests allowing measure-
ments of environmental contaminants and interpretation
of the results by environmental medicine experts.
As HP is believed to be an adult disease, children are
often diagnosed at the chronic stage of the disease
resulting of a long-term exposure to low levels of
inhaled antigens. Children can develop subtle interstitial
inflammatory reactions in the lung without noticeable
symptoms for months [97]. Clinical features in the clas-
sic form include non productive cough, dyspnea,
malaise, asthenia and occasional cyanosis [95]. Lung
function abnormalities are not specific and appear simi-
lar to changes observed in other ILD. HRCT abnormal-
ities vary from ground glass attenuation predominantly
in the mid-upper zone to nodular opacities with signs of
Figure 3 Search for ILD etiology in children. ILD is defined by the presence of diffuse infiltrates on chest radiographs or chest high resolution
computed tomography, and abnormal pulmonary function tests with evidence of a restrictive ventilatory defect (in older children) and/or
impaired gas exchange. The search for etiology requires a systematic step-by-step diagnostic strategy for identifying: exposure-related ILD;
systemic disease-associated ILD; alveolar structure disorder-associated ILD; and ILD specific to infancy.
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the search for serum-precipitating IgG antibodies
against the offending antigen [95]. However, the pre-
sence of these antibodies is considered to be of ques-
tionable clinical relevance for diagnosis, as it is observed
in up to 50% of serum samples of exposed but asympto-
matic individuals. BAL cell profile study typically shows
an increase in total cell count with a remarkable eleva-
tion in the percentage of lymphocytes often over 50%
with a decreased CD4/CD8 ratio [95,97]. However, in
contrast to studies in adults, the CD4/CD8 ratio could
be within the normal range for children [76]. Histo-
pathologic evaluation of lung tissue is usually not neces-
sary for the diagnosis of HP.
At the present time, there is no diagnostic test that is
pathognomonic for HP, and only significant predictors
of HP are identified. The most significant diagnostic
tool is a detailed environmental exposure history. Other
diagnostic features include: positive precipitating antibo-
dies to the offending antigen; recurrent episodes of
symptoms; symptoms occurring 4-8 h after exposure;
occurrence of diffuse parenchymal lung disease by lung
function and HRCT; BAL abnormalities with lymphocy-
tic alveolitis and increased CD8+ T cells.
Medication, drug, radiation and tobacco exposure
Drugs used in inflammatory or cancer pediatric diseases
can cause ILD. They include anti-inflammatory agents
(e.g. aspirin, etanercept), immunosuppressive and che-
motherapeutic agents (e.g. azathioprine, methotrexate,
cyclophosphamide), antibiotics, cardiovascular agents,
and, for teenagers, illicit drugs [99,100]. There are no
distinct clinical, radiographic or pathologic patterns, and
the diagnosis is usually made when a patient is exposed
to medication known to result in lung disease, with a
timing of exposure appropriate for disease development
and elimination of other causes of ILD. Treatment relies
on avoidance of further exposure and corticosteroids in
markedly impaired patients.
Exposure to therapeutic radiation in the management
of pediatric cancer may also results in ILD. Patients pre-
senting within 6 months of therapy generally have radio-
graphic abnormalities with ground glass patterns in both
radiation-exposed and unexposed tissue [101].
The association between tobacco use and ILD is less
well appreciated than the relation with chronic obstruc-
tive pulmonary disease (COPD). In addition, pediatric
patients do not usually have a significant smoking his-
tory to develop respiratory disorders [102].
Systemic disease-associated ILD
Connective tissues disease
Connective tissues disorders (CTD) are a heterogeneous
group of immunologically mediated inflammatory dis-
eases. Their origins are multifactorial with genetic,
constitutional and environmental elements contributing
to their development. CTD refers to any disease that
has the connective tissues of the body as a primary tar-
get of pathology. The connectives tissues are composed
of two major structural proteins, elastin and collagen,
with different types of collagen proteins in each tissue
[103]. Many CTD feature abnormal immune system
activity associated with inflammation. Pulmonary mani-
festations of CTD may include both vascular and inter-
stitial components. From recent reports, the incidence
of ILD in the context of CTD appears to be higher than
previously appreciated [104,105]. Importantly, ILD may
precede the development of clinically obvious CTD,
sometimes by months or years. Table 1 provides infor-
mation on suggestive clinical and serological features in
selected conditions. The main disorders to be consid-
ered in childhood are rheumatoid arthritis, systemic
sclerosis, and systemic lupus erythematosus. The other
include Sjögren syndrome, dermatomyositis and poly-
myositis, ankylosing spondylitis, and mixed connective
tissue disease.
Rheumatoid arthritis Rheumatoid arthritis (RA) is an
inflammatory disorder defined by its characteristic di-
arthroidal joint involvement. It is the most common
CTD in children, but pulmonary involvement is less fre-
quent than in adults. Genetic and environmental factors
seem to be important contributors of disease progres-
sion, with influence of sex (more frequent in male), pre-
sence of two copies of the HLA-DRB1 “shared epitope”
(HLA-DR SE) and anticyclic citrullinated peptide anti-
body (anti-CCP), and possibly tobacco exposure
[106,107].Almost 50% of patients with RA have specific
serologic abnormalities several years before the onset of
joint symptoms, and the findings of elevated serum
levels of IgM rheumatoid factor or anti-CCP is asso-
ciated with a high risk for the development of RA [107].
Systemic sclerosis Systemic sclerosis (SSc) is character-
ized by a progressive dermatologic abnormality [108]. Its
etiology remains unknown; it is believed to be a com-
plex disease in which interactions between environmen-
tal, auto-immune, and genetic factors result in various
disease phenotypes [109]. Although it is a rare disease
in childhood, the diagnosis is based on skin disease.
Cardiopulmonary complications are common and have
been associated with death in young patients. Almost all
patients with SSc have serum antinuclear antibodies.
The other autoantibody markers are listed in table 1.
Recently, the presence of anti-DNA topoisomerase II
autoantibody has been reported to be a key factor in the
development of ILD, in association with class II MHC
status (HLA-DR3, HLA-DPBI) [110].
Systemic lupus erythematosus Systemic lupus erythe-
matosus (SLE) is an auto-immune disorder characterized
by the involvement and dysfunction of multiple organ
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antibody production and immunocomplex formation
leading to an inflammatory process. Diverse clinical phe-
notypes are observed, including a variety of mucocuta-
neous lesions, non erosive arthropathy, renal disease
(glomerulonephritis and interstitial nephritis), lung dis-
ease, pericarditis, and a spectrum of neurologic disor-
ders. Laboratory abnormalities are characterized by the
presence of antibodies reactive to nuclear (ANA) and
cytoplasmic antigens.
Pulmonary vasculitis
Pulmonary vasculitis are observed in vasculitic syn-
dromes that preferentially affect small vessels (arterioles,
venules, and capillaries). They include the anti-neutro-
phil cytoplasmic antibody (ANCA)-associated vasculitis
(Wegener’s granulomatosis, Churg-Strauss syndrome,
and microscopic polyangitis) that share histologic simila-
rities without immune deposits; anti-glomerular base-
ment membrane (GBM) disease; Henoch-Schönlein
purpura and cryoglobulinemia vasculitis. Vasculitic
Table 1 Systemic disease-associated interstitial lung diseases: suggested clinical features and serotypes
CONNESTIVE TISSUE DISEASE MAIN CLINICAL
FEATURES
MAIN SEROLOGICAL
FEATURES
HLA
PREDISPOSITION
Rheumatoid arthritis Arthralgia RF IgM and IgA
Anti-CCP
Anti-keratin
HLA-DR SE
Systemic sclerosis Sclerodactyly ANA-SSc
Anti-centromere
Anti-topoisomerase I
(Scl70) and II
Anti-RNA polymerase
HLA-DR3, HLA-DPB1
Systemic lupus
erythematosus
Skin rash
Arthralgia
Glomerulonephritis
ANA
Anti-native DNA
Anti-nucleosome
Anti-Sm, RNP,
SSA, SSB
Anti-ribosome
CIC
Sjögren syndrome Xerostomia
Serophtalmia
ANA
Anti-SSA, SSB
RF
Anti-RNP
Dermatomyositis
and polymyositis
Muscle weakness
Skin rash
ANA
Anti-Jo1
Anti-Mi2
Anti-SRP
C-ADM-140
Ankylosing
Spondylitis
Bony ankylosis HLA-B27
Mixed connective
tissue disease
Raynaud phenomenon Anti-U1-RNP
PULMONARY
VASCULITIS
MAIN CLINICAL
FEATURES
MAIN SEROLOGICAL
FEATURES
HLA
PREDISPOSITION
Wegener’s
granulomatosis
Glomerulonephritis
Sinusitis
c-ANCA PR3
Churg-Strauss
syndrome
Asthma p-ANCA
Microscopic
polyangitis
Glomerulonephritis
Sinusitis
Skin involvement
p-ANCA
Goodpasture
syndrome
Glomerulonephritis anti-GMB HLA-DRB1*1501
Henoch-Schönlein
purpura
Purpura
Glomerulonephritis
IgA deposition HLA-DRB1
Cryoglobulinemic
vasculitis
Skin involvment
Hepatitis
Glomerulonephritis
Cryoglobulin
Abbreviations: Rheumatoid factor (RF), Immunoglobulin (Ig), Human leucocyte Antigen (HLA), Anticyclic citrullinated peptide (anti-CCP), Antinuclear antibodies
(ANA), Systemic sclerosis (SSc), Smith (Sm), ribonucleoprotein (RNP), circulating immune complex (CIC), anti-histidyl-t-RNA synthetase (Jo1), signal recognition
particle (SRP), anti-U1-ribonucleoprotein antibody (anti-U1-RNP Ab); Cytoplasmic-staining (c) or Perinuclear-staining (p) anti-neutrophil cytoplasmic antibody
(ANCA), anti-glomerular basement membrane (anti-GBM)
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Kawasaki’s disease, polyarteritis nodosa) only occasion-
ally affect the lung [111].
Wegener’sg r a n u l o m a t o s i sWegener’s granulomatosis
(WG) is a rare disease of uncertain cause. It seems to
affect children as much as adults with an increasing
reported incidence around 2.75 cases/million/year,
mostly in teenagers with a reported median age of 14.2
years (4-17 years) [112,113]. It is characterized by
inflammation in a variety of tissues including blood ves-
sels (vasculitis). WG primarily affects the upper respira-
tory tract, lung, and kidneys. The diagnosis is based on
the combination of symptoms and a biopsy of affected
tissue with necrotising granulomatous vasculitis in the
absence of an infectious etiology. The diagnosis is
further supported by positive blood tests for cytoplas-
mic-staining (c)-ANCA PR3 type [114].
Churg-Strauss syndrome Churg-Strauss syndrome
(CSS) is a granulomatous small-vessel vasculitis. The
cause of this allergic angiitis and granulomatosis is not
known, but autoimmunity is evident with the presence
of hypergammaglobulinemia, increased levels of immu-
noglobulin E (IgE), and perinuclear-staining (p)-ANCA.
The diagnosis relies on biopsy evidence for vasculitis
and at least 4 criteria among the following: moderate to
severe asthma, blood eosinophilia (at least 10%), and
nonfixed pulmonary infiltrates with extravascular eosi-
nophils on biopsy [115]. Twenty-nine pediatric cases
have been reported so far in the literature, with lung
involvement in 72% of [116].
Anti-glomerular basement membrane disease Good-
pasture syndrome is a rare disease that involves rapidly
progressive kidney failure along with lung disease and is
characterized by the deposition of anti-GBM antibodies.
Several cases have been reported in the pediatric litera-
ture. The autoantibodies mediate tissue injury by bind-
ing to their reactive epitopes in the basement
membranes. This binding can be visualized as the linear
deposition of immunoglobulin along the glomerular
basement membrane. The principle component of the
basement membrane is type IV collagen which can be
expressed as 6 different chains, from alpha1 to alpha6.
The Goodpasture antigen has been localized to the car-
boxyl terminus of the noncollagenous domain of the
alpha3 chain of type IV collagen. The anti-GBM anti-
body can usually be found in serum [117]. Strong evi-
d e n c ee x i s t st h a tg e n e t i c sp l a ya ni m p o r t a n tr o l e .
Patients with Goodpasture disease have an increased
incidence of HLA-DRB1 compared to control popula-
tions [118].
Granulomatous diseases
Granulomatous disorders are characterized by the pre-
sence of granulomas defined as a focal, compact collec-
tion of inflammatory cells in which mononuclear cells
predominate. Granulomas form as a result of tissue
injury by a wide variety of agents including micro-
organisms, antigens, chemical, drugs and other irritants.
In other situations including sarcoidosis, the etiologic
factors remain to be determined.
Sarcoidosis Sarcoidosis is a chronic inflammatory dis-
ease in which granulomatous lesions can develop in
many organs, mainly the lung. Its cause remains
obscure, and most likely involves environmental and
host factors [119]. The current concept is that a still
unknown stimulus activates quiescent T cells and
macrophages leading to recruitment and activation of
mononuclear cells, with, as a consequence, granuloma
formation, alveolitis, and in some cases interstitial lung
fibrosis [120]. Sarcoidosis is relatively uncommon
among children. Its diagnosis is based on a combination
of suggestive clinical features, with histologically-docu-
mented noncaseating granuloma, in the absence of
other known causes of granuloma formation [121].
The incidence and prevalence of sarcoidosis are
reported to be influenced by age, race and geographic
localization [122]. Although the youngest patients
reported were infants 2 and 3-months old, most of the
cases in children occur in preadolescents and adoles-
cents. From the national patient registry on patients
with sarcoidosis in Denmark during the period 1979-
1994, 81 patients with a confirmed diagnosis were
≤16 years of age [123]. The calculated incidence was
0.29 per 100.000 person-years. In children ≤4 years of
age, the incidence was 0.06; it increased gradually to
1.02 in children aged 14-15 years. Marked racial differ-
ences in the incidence and prevalence of sarcoidosis
have been reported by many authors [122]. Various
reports in the literature also indicate that race and eth-
nicity affect both the patterns of organ involvement and
disease severity. In a follow-up study we have conducted
in 21 children with pulmonary sarcoidosis, 12 children
were Black [124]. Also the number of organs involved
was higher in the Black than in the Caucasian children.
Clinical manifestations in sarcoidosis are the conse-
quences of local tissue infiltration with sarcoid granu-
loma. Therefore, disease expression depends on the
organ or system involved and a variety of symptoms and
physical findings can be observed [125]. The modes of
presentation include non-specific constitutional symp-
toms, alone or associated with symptoms related to spe-
cific organ involvement. In the report of children with
sarcoidosis in Denmark, the most common non specific
symptoms were asthenia, weight loss, and fever [123].
Clinical findings mainly include respiratory manifesta-
tions, lymphadenopathy, skin lesions, ocular and central
nervous system abnormalities. The most common radio-
graphic findings are hilar lymph node enlargements, with
or without lung changes. Lung function abnormalities are
Clement et al. Orphanet Journal of Rare Diseases 2010, 5:22
http://www.ojrd.com/content/5/1/22
Page 12 of 24frequently observed in children with restrictive pulmon-
ary pattern and abnormal diffusing capacity [126]. Other
investigations such as BAL documenting a lymphocytic
alveolitis with increased CD4/CD8 ratio, and elevated
serum angiotensin-converting enzyme may provide addi-
tional evidence of sarcoidosis [127].
Other granulomatous disorders in children An u m b e r
of pathological situations are associated with granuloma-
tous disorders defined by the presence of non-caseating
granuloma in biopsied tissues. Infections are the main
causes of other granulomatous diseases, and are in some
cases related to disorders of neutrophil function such as
chronic granulomatous disease (CGD) [128]. Most chil-
dren with CGD present with recurrent bacterial and
fungal infections. The most frequently encountered
pathogens are Staphylococcus aureus, Aspergillus, Bur-
kholderia cepacia, and enteric gram negative bacteria
[129]. The most prominent pulmonary lesions include
an extensive infiltration of the lung parenchyma and
hilar adenopathy. In some situations, a homogeneous
distribution of small granulomatous lesions can occur,
with a radiological appearance of miliary tuberculosis.
The other granulomatous diseases can be seen in
other described diseases, such as immune disorders
(including Crohn’s disease and histiocytosis X), HS
pneumonitis, vasculitis disorders or neoplasms.
Metabolic disorders
Lysosomal diseases Gaucher’s disease is an autosomal
recessive disease and the most common of the lysosomal
storage diseases. It is caused by a genetic deficency of the
enzyme lysosomal gluco-cerebrosidase that catalyses the
breakdown of glucocerebroside, a cell membrane consti-
tuent of red and white blood cells. The consequence is
an accumulation of glucocerebroside in reticuloendothe-
lial cells, leading to excessive deposition of fatty material
in the spleen, liver, kidneys, lung, brain and bone mar-
row. Pulmonary expression is mainly characterized by
physiologic involvement (reduction in lung the diffusion
capacity and the functional residual volume). Lung
imaging may show interstitial changes [130].
Niemann-Pick diseases are genetic diseases primarily
due to deficiency of sphingomyelinase resulting in the
accumulation of sphingomyelin within lysosomes in
the macrophage-monocyte phagocyte system, mainly
the brain, spleen, liver, lung, and bone marrow. Histol-
ogy demonstrates lipid laden macrophages in the mar-
row, as well as “sea-blue histiocytes” on pathology. The
infantile form with a dominant neurologic expression
is rapidly fatal. In older patients, cases of ILD have
been reported [131].
Hermansky-Pudlak syndrome is a heterogeneous
group of autosomal recessive disorders associated with
accumulation of a ceroid-like substance in lysosomes of
a variety of tissues. It is characterized by albinism,
bleeding tendency associated to poor platelet aggrega-
tion and systemic complications associated to lysosomal
dysfunction. A chronic inflammatory process may
explain the progressive development of ILD and fibrosis
[132].
Familial hypercalcemia with hypocalciuria Familial
hypercalcemia with hypocalciuria is caused by autosomal
dominant loss-of-function mutations in the gene encod-
ing the calcium-sensing receptor (CASR), a G-protein
coupled membrane receptor expressed in many tissues
[133]. Loss-of-function mutations in CASR impair the
feedback inhibition of parathyroid hormone secretion in
response to a rise in the blood calcium concentration.
The result is hypercalcemia associated with inappropri-
ately normal or mildly elevated levels of parathyroid
hormone. In the kidneys, mutations in CASR prevent
the feedback inhibition of calcium reabsorption in situa-
tion of hypercalcemia, leading to relative hypocalciuria.
Respiratory symptoms are usually mild and associated
with reduction in the lung diffusion capacity. Lung
histology indicates the presence of foreign body giant
cells and mononuclear cells infiltrating the alveolar
interstitium, without circumscribed granulomas.
Langerhans’-cell histiocytosis
Langerhans’-cell histiocytosis is part of the histiocytosis
syndromes, which are characterized by an abnormal
proliferation of Langerhans’ cells [134]. The Langerhans
cells are differentiated cells of monocyte-macrophage
lineage that function as antigen-presenting cells. The
origin of the expanded population of Langerhans’ cells
is unknown; in adults, the only consistent epidemiologic
association is with cigarette smoking. These cells may
form tumors, which may affect various parts of the
body. Most cases of pediatric Langerhans’-cell histiocy-
tosis are observed in children between ages 1 and
15 years, with usually bone involvement (80%) including
t h es k u l l .T h et u m o r sp r o d u ce a punched-out appear-
ance on bone X-ray, and can cause fracture without
apparent traumatism. Langerhans’-cell histiocytosis can
also affects various organs including the lung [135].
Children with pulmonary Langerhans’-cell histiocytosis
present in a variety of ways. They can be asymptomatic
or present common symptoms such as nonproductive
cough and dyspnea. HRCT of the chest is a useful and
sensitive tool for the diagnosis. Indeed, the combination
of diffuse, irregularly shaped cystic spaces with small
peribronchiolar nodular opacities, predominantly in the
middle and upper lobe, is highly suggestive of pulmon-
ary Langerhans’-cell histiocytosis [63]. Other abnormal-
ities include ground-glass attenuation. The presence of
increased numbers of Langerhans’ cells in BAL fluid
(identified by staining with antibodies against CD1a)
with a proportion greater than 5 percent is also strongly
suggestive of pulmonary Langerhans’-cell histiocytosis.
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taining a mixed population of cells with variable num-
bers of Langerhans’ cells, eosinophils, lymphocytes,
plasma cells, fibroblasts, and pigmented alveolar
macrophages.
ILD associated with other organ diseases
Several forms of ILD have been reported to occur with
inflammatory bowel diseases (Crohn’s disease) and celiac
disease [136]. Primary biliary cirrhosis and chronic
hepatitis have also been reported to be associated with
parenchymal lung dysfunction [137,138]. In addition,
there are reports on ILD in association with neurocuta-
neous disorders (tuberous sclerosis, neurofibromatosis,
ataxia-telangiectasia) and amyloidosis [139].
Alveolar structure disorder-associated ILD
Depending on the causes, the components of the alveo-
lar structure (the epithelium and the alveolar space, the
interstitium, and the pulmonary capillary endothelium)
can be involved differently and can serve as primary tar-
gets of the underlying pathological processes. Based on
history, clinical presentation, BAL data, and, most
important, on information from lung tissue studies, the
disorders can be gathered in groups according to predo-
minant structural targets (Figure 4).
Disorders affecting primarily the alveolar epithelium and
the alveolar space
The disorders affecting primarily the alveolar epithelium
and the alveolar space share common histopathological
description, with preserved pulmonary architecture,
hyperplasia of type 2 AEC, interstitial infiltrates com-
posed of immuno/inflammatory cells and scattered myo-
fibroblasts, and the alveolar space filled with either
immuno/inflammatory cells, desquamated materials, or
components derived from surfactant lipid and protein
complex. In the coming years, it is likely that the list of
disorders will expand rapidly with the availability of spe-
cific tissue markers. Currently, the following grouping
can be proposed: infections,s u r f a c t a n td i s o r d e r s ,a n d
eosinophilic lung diseases.
Infections T h er o l eo fi n f e c t i o n ,m a i n l yv i r a l ,i nt h e
development and progression of ILD is sustained by a
number of human and experimental reports. From
recent knowledge, it is strongly suggested that latent
viral infections may be involved in the pathogenesis of
ILD, through targeting of the alveolar epithelium. The
main virus implicated include adenovirus, members of
human herpes virus family (Epstein-Barrr virus and
cytomegalovirus), and respiratory syncitial virus [140].
Number of other viruses can also be involved such as
Influenza A, hepatitis C, or even Human Immunodefi-
ciency Virus (HIV) in immunocompetent children
[141-144].
Human adenovirus being predominantly respiratory
pathogens, adenovirus infections can cause a variety of
pulmonary symptoms and can persist for long periods
of time. Several studies in adult patients have indicated
that the adenovirus gene product E1A could be detected
Figure 4 Alveolar structure disorder-associated ILD. Depending on the causes, the alveolar structure components can be involved differently
and serve as primary targets of the underlying pathological processes. Based on history, clinical presentation, BAL and lung tissue information,
the disorders can be gathered in groups according to the predominant alveolar targets: epithelium, vascular or interstitial components.
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cases of idiopathic pulmonary fibrosis. The causative
role of the virus in the initiation of the disease remains
uncertain, but it may be an important factor in its pro-
gression as treatment with corticosteroids may make
patients more susceptible to adenovirus infection or
reactivation from latency. E1A has been shown to
increase the production of TGF-b and to induce lung
epithelial cells to express mesenchymal markers, thereby
contributing to remodeling of the alveolar structure
[145]. Isolation of the virus from the throat and serolo-
gic studies are diagnostic supportive, but the diagnosis
is confirmed by the detection of the virus in lung
tissues.
Epstein-Barrr virus (EBV) and cytomegalovirus (CMV)
are widespread pathogens that share the characteristic
ability of herpesviruses to remain latent within the body
over long periods. In mice, the control of herpesviruses
replication have also been reported to be associated
with the arrest of lung fibrosis [146]. EBV is present in
all populations, infecting more than 95% of individuals
within the first decades of life. Infection by CMV is
reported in 60% of individuals aged 6 and older and
more than 90% of aged individuals have antibodies
against CMV. In addition, CMV is also the virus most
frequently transmitted to a developing fetus. Most
healthy people who are infected by EBV and CMV after
birth have no symptoms, but infection is important to
certain high-risk groups of infants and immunocompro-
mised individuals. Several studies in the adult literature
have reported an increased incidence of EBV and CMV
infection in patients with pulmonary fibrosis, associated
with virus DNA-positive lung tissue biopsies in several
cases [147]. However, so far, no evidence of causal rela-
tionship between viruses and pulmonary fibrosis has
been provided.
Respiratory syncytial virus (RSV) is the most common
cause of viral lower respiratory tract infection. It affects
people of all ages, and can cause severe disease in
infants, in older immunodeficient children and the
elderly. An intriguing feature of RSV infection is the
susceptibility of previously infected individuals to rein-
fection with antigenically closely related viruses or the
identical virus strain. Recently, increased interest has
been focused on the contribution of persistent RSV in
several chronic lung diseases including chronic obstruc-
tive pulmonary disease [148]. The role of RSV in the
physiopathology of theses disorders as well as and the
mechanisms of its persistence remain to be elucidated
[149]. Interestingly, in a recent work on the histopathol-
ogy of untreated human RSV infection, the presence of
the virus in AEC has been documented [150]. From
these various data, a role of RSV in the development of
ILD needs to be investigated. Immunostaining with
RSV-specific antibodies of tissues from lung biopsy
should be proposed.
Among the other pathogens, Chlamydophila pneumo-
niae and Mycoplasma pneumoniae are currently draw-
ing increasing consideration. They are frequent causes
of community acquired pneumonia in children. Before
the age of 10 years, almost 70% of children have had
Chlamydophila pneumoniae infection based on serologi-
cal studies [151]. These pathogens are intracellular
organisms that primarily infect respiratory epithelial
cells and alveolar macrophages and have the propensity
to persist within several cell types such as macrophages.
They are well known to cause a wide variety of respira-
tory manifestations, with possible progression towards
diffuse parenchymal diseases associated with interstitial
infiltrates on chest imaging and reduction in the lung
diffusion capacity [152]. Regarding Legionella pneumo-
philia infection, progression towards ILD has been infre-
quently reported in adult patients.
Results from recent studies provided evidence that
viruses can infect the alveolar epithelium and may be
documented in lung tissues from patients using virus
DNA detection and immunohistochemistry. A number
of specific antibodies are currently available and should
prompt to investigate the presence of the above cited
viruses in the lung tissues from children with ILD.
Surfactant disorders Surfactant disorders include
mainly genetic surfactant protein disorders and pulmon-
ary alveolar proteinosis
The deficiency in SP-B is a rare autosomal recessive
condition known to be responsible for lethal neonatal
respiratory distress. Rare survivals have been described
in partial deficiencies [153,154]. The SFTPC mutation
I73T (c.218 T > C) is the more prevalent mutation.
Others are described in only one family. The phenotype
associated with SFTPC mutations is extremely heteroge-
neous leading from neonatal fatal respiratory failure to
children and adults chronic respiratory disease with ILD
[45]. Recessive mutations in the ABCA3 gene were first
attributed to fatal respiratory failure in term neonates
but are increasingly being recognized as a cause of ILD
in older children and young adults. Over 100 ABCA3
mutations have been identified in neonates with respira-
tory failure and in older children with ILD [86,155-161].
Mutations in the TTF-1 gene are associated with “brain-
lung-thyroid syndrome” which combines congenital
hypothyroidism, neurological symptoms (hypotonia,
chorea), and ILD of variable intensity [162-168]. So far,
few mutations have been reported, mostly in exon 3
[169,170].
Pulmonary alveolar proteinosis (PAP) is a rare lung
disorder characterized by alveolar filling with floccular
material derived from surfactant phospholipids and pro-
tein components. PAP is described as primary or
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and inhalation of mineral dusts. Recently, the impor-
tance of granulocyte/macrophage colony-stimulating fac-
tor (GM-CSF) in the pathogenesis of PAP has been
documented in experimental models and in humans.
GM-CSF signaling is required for pulmonary alveolar
macrophage catabolism of surfactant. In PAP, disruption
of GM-CSF signaling has been shown, and is usually
caused by neutralizing autoantibodies to GM-CSF.
Therefore, the emerging concept is that PAP is an auto-
immune disorder resulting in macrophage and neutro-
phil dysfunction. In a recent report, it has been reported
that GM-CSF autoantibodies are normally present in
healthy individuals, but at lower levels than in PAP
patients [171]. In addition, in vitro experiments indi-
cated that these autoantibodies reduce GM-CSP signal-
ing similarly in healthy individuals and in PAP patients.
At levels above a critical threshold, GM-CSF autoantibo-
dies are associated with multiple impaired GM-CSF
dependent myeloid function [172]. Several cases of
genetic defects in the common beta chain for the GM-
CSF receptor have been documented [173].
Eosinophilic lung diseases Eosinophilic lung diseases
constitute a diverse group of disorders of various ori-
gins. The diagnosis is suggested by the presence of pul-
monary infiltrates on chest imaging and peripheral
eosinophilia. It is confirmed by the presence of
increased amounts of eosinophils in BAL and/or lung
tissue eosinophilia. In this section, eosinophilic vasculitis
w i l ln o tb ed i s c u s s e d( s e ec h a p t e r6 . 2 . 2 ) .T h es e a r c hf o r
an etiology includes a combination of clinical and
laboratory investigations. Eosinophilic lung diseases of
known cause in children include mainly allergic bronch-
opulmonary aspergillosis, parasitic infections and drug
reactions. Eosinophilic lung diseases of unknown cause
comprise Loeffler syndrome (characterized by migrating
pulmonary opacities), acute eosinophilic pneumonia,
and chronic eosinophilic pneumonia [174,175]. The
idiopathic hyper-eosinophilic syndrome is a rare disor-
der observed mainly in adults; it is characterized by pro-
longed eosinophilia and a multiorgan system
dysfunction due to eosinophil infiltration with pulmon-
ary involvement documented in almost half of the
patients [176,177].
Disorders affecting primarily the alveolar vascular
components
Alveolar capillary dysplasia and pulmonary capillary
hemangiomatosis The pulmonary capillaries form a
dense sheet-like meshwork composed of short intercon-
nected capillary segments. The capillary meshes are
wrapped over the alveoli, with only a single sheet of
capillaries between adjacent alveoli on the same alveolar
duct. Impaired development of this vascular network
can be caused by genetic defects, prematurity or injury.
Aberrant angiogenesis documented in pediatric patients
include mainly alveolar capillary dysplasia, and pulmon-
ary capillary hemangiomatosis [178]. Alveolar capillary
dysplasia is a rare disorder, presenting with persistent
pulmonary hypertension of the newborn [179]. The
strongest diagnostic features are poor capillary apposi-
tion and density, allied with medial arterial hypertrophy
and misalignment of pulmonary vessels [180]. Pulmon-
ary capillary hemangiomatosis is also a rare disease that
is characterized by proliferation of capillary-sized vessels
within the alveolar walls of the lung [181]. Intimal thick-
ening and medial hypertrophy of the small muscular
pulmonary arteries are present resulting in elevated pul-
monary vascular resistance. Most cases appear sporadic.
Chest imaging shows nodular pulmonary infiltrates and
septal lines. A definitive diagnosis can be made only by
histologic examination. Interestingly, capillary prolifera-
tion in the alveolar wall has been reported in hereditary
haemorrhagic telangiectasia [182].
Lymphatic disorders Alveolar structure formation is
characterized by refinement of the gas exchange unit
and functional adaptation of endothelial cells into ves-
sels including pulmonary lymphatics. The pulmonary
lymphatic network promotes efficient gas exchange
through maintaining interstitial fluid balance. Lymphatic
disorders can be classified as primary or secondary.
Congenital errors of lymphatic development can lead
to primary pulmonary lymphatic disorders that include
lymphangiomas and lymphangiomatosis, lymphangiecta-
sis, and lymphatic dysplasia syndrome [183,184]. Lym-
phangiomas are focal proliferations of well differentiated
lymphatic tissue, and lymphangiomatosis describes the
presence of multiple lymphangiomas. Most of these
disorders are discovered in fetuses or during the early
postnatal period. Lymphangiectasis is characterized by
pathologic dilation of lymphatics. The term “lymphatic
dysplasia syndrome” includes congenital chylothorax,
and the yellow nail syndrome (a triad of idiopathic
pleural effusions, lymphedema, and dystrophic nails)
[185]. Secondary forms of lymphatic disorders result
from a variety of processes such as chronic airway
inflammation that impair lymph drainage and increase
lymph production [186].
Diffuse alveolar hemorrhage syndromes Diffuse alveo-
lar hemorrhage (DAH) syndromes are caused by the dis-
ruption of alveolar-capillary basement membrane as a
consequence of injury to the alveolar septal capillaries,
and less commonly to the arterioles and veinules. The
hallmarks are intra-alveolar accumulation of red blood
cells, fibrin, and hemosiderin-laden macrophages. It is
important to point out that approximately one third of
patients with DAH do not manifest hemoptysis, and
BAL can be extremely helpful if this entity is suspected
by showing the presence of siderophages or red blood
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tion with systemic findings or without evidence of asso-
ciated diseases.
In children, situations of DAH in the context of other
disorders are reported in several forms of vasculitis dis-
cussed above. Other disorders that can also be accompa-
nied by DAH include pulmonary hypertension and
congenital heart diseases, pulmonary veino-occlusive
disease, arteriovenous malformations and hereditary
haemorrhagic telangiectasia, coagulation disorders, and
celiac disease [187].
In the absence of systemic findings, isolated pulmon-
ary capillaritis should be discussed with the search for
positivity of the antiglomerular basement membrane
antibody with linear deposits in the lung tissue biopsy
as well as suggestive serologic features such as p-ANCA
antibodies [188].
Idiopathic pulmonary hemosiderosis is a diagnosis of
exclusion based on patient presentation with acute, sub-
acute, or recurrent DAH, on the results of lung biopsy
showing evidence of ‘bland’ pulmonary hemorrhage (ie,
without capillaritis or vasculitis), and after exclusion of
the conditions listed above [189]. In this situation, red
blood cells leak into the alveolar space without evidence
of damage and/or inflammation of the alveolar capil-
laries. In addition, the diagnosis of idiopathic pulmonary
hemosiderosis can only be considered after exclusion of
diseases induced by environmental factors such as pesti-
cide and cow’s milk (Heiner’s syndrome) [190]. This
syndrome is a hypersensitivity disease that affects pri-
marily infants, and is caused by antibodies to cow’sm i l k
proteins. The diagnosis is supported by positive milk
precipitin test and rapid improvement of symptoms and
pulmonary infiltrates on chest imaging after exclusion of
milk proteins.
Disorders affecting primarily the alveolar interstitial
components
In the resolution phase of tissue injury, elimination of
mesenchymal cells and recruited inflammatory cells is
essential for restoration of normal cellular homeostasis.
Dysregulated repair process in ILD is associated with
accumulation and dysfunction of interstitial fibroblasts
[191]. In the coming years, it is likely that progress in
the understanding of the mechanisms involved in the
impaired myofibroblast apoptosis as well as evasion of
these cells from immune surveillance will open new
areas of investigations and will provide support for the
characterization of disorders that affect primarily the
alveolar interstitial components in pediatric ILD. Indeed,
recently, distinct intrinsic differences in gene expression
pathways has been reported between control and lung
fibrosis myofibroblasts which suggests that ILD myofi-
broblasts are pathological cells with fundamental
changes [192].
ILD specific to infancy
In the context of ILD, pulmonary interstitial glycogeno-
sis, neuroendocrine cell hyperplasia, and chronic pneu-
monitis in infancy have been reported to be exclusively
observed in very young children [8].
Pulmonary interstitial glycogenosis (PIG) is a non
lethal disease, reported in neonates with respiratory dis-
tress syndrome developed shortly after birth [193,194].
Very few cases are described so far but it seems to have
a male preponderance [195]. The histological hallmark
of pulmonary interstitial glycogenosis is the accumula-
tion of monoparticulate glycogen in the interstitial cells
on lung biopsy. It is thought to represent a maturation
defect of interstitial cells that leads them to accumulate
glycogen within their cytoplasm [8,196]. It is discussed
that PIG could meet “chronic pneumonitis in infancy”
as this remains a generalized term [87]. As well, PIG
could be considered as a premature lung disease, but
more than half of published cases were in term infants
[195,197,198]. The long term consequences in these
infants need to be ascertained.
Neuroendocrine cell hyperplasia of infancy (NCHI) is
also a non lethal disease characterized by tachypnea
without respiratory failure. The human airway epithe-
lium contains highly specialized pulmonary neuroendo-
crine cells (PNEC) system. It’s function remains
unknown but is hypothysed to act in modulation of fetal
lung growth and in post-natal stem cell condition [199].
The PNEC system permits synthesis and release of sero-
tonin and neuropeptides such as bombesin [200]. As
normal bombesin levels decrease after mid-gestation, its
overexpression in NCHI could be attributed to a non-
regression of neuroendocrine cells [201]. Clinical pre-
sentation is typically a respiratory distress in post-natal
young infant (mean age 3.8 months in a large serie, but
cases in older children have been reported [202]. HRCT
shows patchy centrally ground-glass opacifications and
air trapping [203]. On lung biopsy, the histological
abnormality is hyperplasia of neuroendocrine cells
within bronchioles documented by bombesin immuno-
histochemistry. The follow-up reveals in some cases the
persistence of tachypnea ando x y g e nr e q u i r e m e n tf o r
several months. Usually, there is a good prognosis
[7,8,196,202].
Chronic pneumonitis in infancy was first described by
Katzenstein et al. [4]. The clinical and radiologic fea-
tures are similar to those observed in other forms of
ILD. Specific histologic abnormalities include diffuse
thickening alveolar septa, hyperplasia of type 2 AEC,
and presence of primitive mesenchymal cells within the
alveolar septa. In some cases, foci of pulmonary protei-
nosis-like material have been observed in air spaces.
The prognosis has been reported to be poor with a high
mortality rate.
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ment and growth abnormalities encompass a broader
spectrum of respiratory manifestations and are more
adequately integrated in the classification of diffuse lung
diseases [8].
Treatment and outcome
General measures
Management of children with ILD includes administra-
tion of oxygen for chronic hypoxaemia, and mainte-
nance of nutrition with an adequate energy intake,
Immunization with influenza vaccine on an annual basis
is recommended along with other routine immuniza-
tions against major respiratory pathogens [11]. In addi-
tion, aggressive treatment of intercurrent infections and
strict avoidance of tobacco smoke and other air pollu-
tants are strongly recommended.
Pharmacologic therapy
A very few children do not require any treatment and
recover spontaneously. In the majority of cases, treat-
ment with immunosuppressive, anti-inflammatory, or
anti-fibrotic drugs is required for weeks, months or even
years [1,9,61]. Various drugs discussed below can be
used, but no guidelines for treatment of ILD in children
have been proposed so far. The major reason is the very
limited number of pediatric patients available for a pro-
spective clinical trial. In addition, controlled studies with
a placebo arm are unacceptable because of the poor
prognosis of untreated cases and the reported efficacy of
anti-inflammatory therapies in a number of pediatric
ILD.
At the present time, the main therapeutic strategy is
based on the concept that suppressing inflammation
may most likely prevent progression to fibrosis. Among
the anti-inflammatory agents used in pediatric ILD, ster-
oids are the preferred choice, administered orally and/or
intravenously. This has been well illustrated by the
results of the ERS Task Force on pediatric ILD [9]. Oral
prednisolone is most commonly administered at a dose
of 1-2 mg/kg/day [1]. Children with significant disease
are best treated with pulsed methylprednisolone at least
initially [61,204]. This is usually given at a dose of 10-30
mg/kg/day for 3 days consecutively at monthly intervals.
The minimum number of cycles recommended is 3 but
treatment may need to be continued for a longer period
of 6 months or more depending on response. When the
disease is under control, thed o s a g eo fm e t h y l p r e d n i s o -
lone can be reduced or the time between cycles can be
spaced out. The disease may then be controlled with
oral prednisolone preferably given as an alternate day
regime. In few cases oral prednisolone is used from the
beginning simultaneously with intravenous methylpred-
nisolone but this is only recommended in those with
very severe disease. Methylprednisolone may be effective
when other forms of steroids administration fail without
significant side effects.
An alternative to steroids is hydroxychloroquine with
a recommended dose of 6-10 mg/kg/day. Individual case
reports have described a response to hydroxychloro-
quine even in the presence of steroid resistance
[1,205,206]. Some groups have proposed to base the
decision as to which agent to use on the lung biopsy
findings, with a preference for steroids in case of large
amount of desquamation and inflammation and for
hydroxychloroquine if increased amounts of collagen
representing pre-fibrotic change are found. However, as
documented in the ERS Task Force on pediatric ILD,
the preferred choice between steroids or hydroxychoro-
quine in children is highly dependent on the expertise
of the center in charge of the patient, and does not
seem to be oriented by the histopathological pattern [9].
In case of severe disease, steroids and hydroxychloro-
quine may be associated. In situations of inefficiency of
steroids and hydroxychloroquine, other immunosuppres-
sive or cytotoxic agents such as azathioprine, cyclopho-
sphamide, cyclosporine, or methotrexate may be used.
These treatments have been used mainly in situation of
autoimmune disorders.
Promising therapeutic options include macrolides.
Indeed, these antibiotics have been shown to display a
number of anti-inflammatory and immunomodulatory
actions. Although the mechanisms and cellular targets
specific to macrolide activity remain to be elucidated,
beneficial effects in several chronic lung diseases includ-
ing chronic obstructive pulmonary diseases (COPD) and
cystic fibrosis have been reported [207,208]. Of interest
is the ability of macrolides to accumulate in host cells
including epithelial cells and phagocytes. In a recent
report, a favorable response to treatment with clarithro-
mycine has been described in an adult patient with DIP
[209]. Other new therapeutic strategies currently pro-
posed in adult patients target fibrogenic cytokines. The
Th1 cytokine interferon-g has an antifibrotic potential
through suppression of Th2 fibrogenic functions.
Antagonists to TGF-b include pirfenidone and decorin.
The use of molecules directed against TNF-a such as
the soluble TNF-a receptor agent etanercept is also
under investigation. To date, there are no reports on the
use of these novel therapies in pediatric ILD. Finally, in
the coming years, it is likely that an expanding number
of molecules aimed at favoring alveolar surface regen-
eration and repair through activation and proliferation
of tissue-resident (progenitor) cells will come out.
Other specific treatment strategies
Depending on the underlying diseases, several specific
treatment strategies needs to be considered. These
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nosis, which has been reported to be effective by remov-
ing the material from the alveolar space [210]. GM-CSF
has also been shown of interest in this disease [171].
Other strategies such as interferon-a for pulmonary
haemangiomatosis are effective [211].
In recent years, lung transplantation has emerged as a
viable option in children of all ages, even in young
infants, and lung or heart-lung transplantation may be
offered as an ultimate therapy for end-stage ILD [11].
The outcome and survival do not seem to be different
from those reported in conditions others than ILD,
although comparisons are difficult to establish due to
the limited number of reported cases.
Outcome
Response to treatment and outcome can be evaluated in
children based on several criteria such as decrease in
cough and dyspnea, increase in oxygenation at rest and
sleep, and changes in pulmonary function tests [1,11].
Improvement on thoracic HRCT may also be seen, but
tends to occur over a much longer period of time.
Reports in pediatric ILD have not shown a good correla-
tion between histological findings and outcome. Some
children with relatively severe fibrosis on lung biopsy
make good progress, whereas others with mild desqua-
mation have a poor outcome. This is probably due to
t h ev a r i a b l es e v e r i t yo ft h ed i s e a s ei nd i f f e r e n tp a r t so f
the lung especially in relation to the particular area
biopsied, despite HRCT guidance. Overall a favorable
response to corticosteroid therapy can be expected in
40-65% of cases, although significant sequelae such as
limited exercise tolerance or the need for long-term
oxygen therapy are often observed. Reported mortality
rates are around 15%. The outcome for infants is more
variable [1,61].
Conclusion
Pediatric ILD comprises a large spectrum of disorders,
with compelling evidence that some of these disorders
are observed more frequently in infants, while others are
more specific to older children. Ongoing basic research
will provide new insights into the molecular basis of
ILD pathogenesis (including genetic factors causing
familial disease) in children, and is expected to identify
important preclinical markers of disease, pathways of
disease regulation, and novel potential targets for thera-
peutic intervention. For the future, there is a strong
need for international collaboration which will allow
collecting sufficiently large cohorts of patients with spe-
cific entities in order to perform proper therapeutic
trials. As a prerequisite, however, a clear and standar-
dised classification of the histopathology of the underly-
ing conditions is critical. Such multicenter trials will
help to reduce the still considerable morbidity and mor-
tality in children with ILD.
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